CN109549206A - A kind of thrombolysis and the functional food and preparation method thereof for preventing cardiovascular disease - Google Patents
A kind of thrombolysis and the functional food and preparation method thereof for preventing cardiovascular disease Download PDFInfo
- Publication number
- CN109549206A CN109549206A CN201710881042.4A CN201710881042A CN109549206A CN 109549206 A CN109549206 A CN 109549206A CN 201710881042 A CN201710881042 A CN 201710881042A CN 109549206 A CN109549206 A CN 109549206A
- Authority
- CN
- China
- Prior art keywords
- extract
- thrombolysis
- cardiovascular disease
- functional food
- preventing cardiovascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 72
- 230000002537 thrombolytic effect Effects 0.000 title claims abstract description 69
- 235000013376 functional food Nutrition 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 82
- 230000002265 prevention Effects 0.000 claims abstract description 41
- 235000013557 nattō Nutrition 0.000 claims abstract description 26
- 241000237636 Pheretima Species 0.000 claims abstract description 23
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 21
- 229940038487 grape extract Drugs 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 229920002472 Starch Polymers 0.000 claims description 15
- 235000019698 starch Nutrition 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 229940086319 nattokinase Drugs 0.000 claims description 10
- 108010073682 nattokinase Proteins 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 229930003944 flavone Natural products 0.000 claims description 7
- 235000011949 flavones Nutrition 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 6
- 150000002212 flavone derivatives Chemical class 0.000 claims description 6
- 229920002414 procyanidin Polymers 0.000 claims description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 6
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims description 5
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000020985 whole grains Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 26
- 238000012360 testing method Methods 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 2
- 208000007536 Thrombosis Diseases 0.000 description 30
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 230000006870 function Effects 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 13
- 241001092040 Crataegus Species 0.000 description 12
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 12
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 12
- 235000009685 Crataegus X maligna Nutrition 0.000 description 12
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 12
- 235000009486 Crataegus bullatus Nutrition 0.000 description 12
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 12
- 235000009682 Crataegus limnophila Nutrition 0.000 description 12
- 235000004423 Crataegus monogyna Nutrition 0.000 description 12
- 235000002313 Crataegus paludosa Nutrition 0.000 description 12
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 239000002994 raw material Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 241000219095 Vitis Species 0.000 description 7
- 235000009754 Vitis X bourquina Nutrition 0.000 description 7
- 235000012333 Vitis X labruscana Nutrition 0.000 description 7
- 235000014787 Vitis vinifera Nutrition 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000004224 protection Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011122 softwood Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 239000003527 fibrinolytic agent Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000008440 Crataegus cuneata Nutrition 0.000 description 2
- 244000160089 Crataegus cuneata Species 0.000 description 2
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000756042 Polygonatum Species 0.000 description 2
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 2
- 241000037831 Polygonatum sibiricum Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 108010070324 lumbrokinase Proteins 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108700022737 rat Fat1 Proteins 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 206010000598 Acrodynia Diseases 0.000 description 1
- 231100000455 Acrodynia Toxicity 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000045500 Diseae Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001446187 Kermes Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- OEERIBPGRSLGEK-UHFFFAOYSA-N carbon dioxide;methanol Chemical compound OC.O=C=O OEERIBPGRSLGEK-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 102000005525 fibrillarin Human genes 0.000 description 1
- 108020002231 fibrillarin Proteins 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- CXORMDKZEUMQHX-UHFFFAOYSA-N kermesic acid Chemical compound O=C1C2=C(O)C(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CXORMDKZEUMQHX-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The embodiment of the present invention provides a kind of thrombolysis and prevents the functional food and preparation method thereof of cardiovascular disease, it is related to health product technology field, the thrombolysis and the functional food for preventing cardiovascular disease are proved through in vitro test and animal function test, healthcare function with thrombolysis and prevention cardiovascular disease, can effectively thrombolysis and its prevention cardiovascular disease and safely and effectively, have no toxic side effect.The thrombolysis and the functional food for preventing cardiovascular disease include the effective component of following percentage: natto extract 5 ~ 25%, pheretima protein extract 4 ~ 15%, grape extract 0.1 ~ 10%, haw thorn extract 0.1 ~ 10%, Rhizoma Polygonati extract 0.1 ~ 10%.
Description
Technical field
The present invention relates to health product technology field more particularly to a kind of thrombolysis and the functional foods of prevention cardiovascular disease
And preparation method thereof.
Background technique
Thrombus refers to the grumeleuse that blood constituent in human body (blood platelet, coagulation factor) is formed in blood vessel or heart, embolism
Refer in the heart, lung or the cardiovascular interior thrombus formed, completely or partially falls off, flow to distal end with blood, block lumen of vessels.
Will not cause apparent symptom although internal most of thrombus are smaller, some thrombotic diseases disability rates and
The death rate is higher, is one of the disease for seriously endangering human health.It common are coronary artery disease to form thrombus and cause the heart
Muscle infarction (AMI) or angina pectoris；Cranial vascular disease forms thrombus, i.e. cerebral thrombosis apoplexy；Pulmonary embolism causes lung infraction or anxious
Property lung original heart disease；Limb artery thrombosis and embolism cause acrodynia or necrosis；Limbs venous thronbosis causes office
Portion's oedema and pain；Diffusivity thrombus occurs in whole body capillary, forms unique disease i.e. disseminated intravascular coagulation (DIC).The heart
Popular name for and cranial vascular disease are to lead to first and the third-largest reason of human death, two class diseases it is initially most all due to blood and
Blood vessel property change, formed thrombus, gradually cause vascular sclerosis, protrusion spot (plaque) development and eventually lead to blood flow cessation
It is progressive narrow.
The cardiovascular disease due to caused by thrombus has seriously affected the life and quality of life of the mankind, cardiovascular disease
It has been the No.1 cause of the death in the whole world, has died of the number of cardiovascular disease every year more than any other cause of the death.Disease caused by thrombus
Therapeutic modality be mainly drug therapy；Although drug therapy works comparatively fast, all there is a degree of side effect, centering is old
Year, the quality of life of people had a certain impact, and in the economic level of both macro and micro, cardiovascular disease makes low income and medium income
The economic back heavy burden of country and family.Meanwhile in this inferior health epoch, as people are to the attention rate of own health
It increases, prevention of diseae has been rooted in the hearts of the people, and therefore, functional food and health food have begun ingredient people and adjust own health
A kind of means.
Currently, thrombus dissolving, the product of reducing blood lipid are numerous on the market, simultaneously as cardiovascular disease caused by thrombus
Disease incidence rises year by year, but the excessive publicity product efficacy of product of pre- preventing thrombosis on the market, and product quality is very different, effect
Approach is unintelligible, seriously misguides the consumer, and brings injury to its body and psychology, and cardiovascular disease increases increasingly, serious shadow
The quality of life of crowd has been rung, therefore, a functional food with certain thrombolysis prevention cardiovascular disease has been developed and has become
A kind of market trend.
The product of anti-bolt prevention cardiovascular disease is broadly divided on the market at present: 1) thrombolytic drug, predominantly anticoagulant
Object and thrombolytic drug etc.；2) blood fat reducing healthcare food, predominantly deep sea fish oil, procyanidine class product, Chinese medicinal plant class product
Deng；3) function assessment food, predominantly Nattokinase, pheretima protide product.
Although thrombus dissolving, the product of reducing blood lipid are numerous on the market, simultaneously as the hair of cardiovascular disease caused by thrombus
Sick rate rises year by year, but the excessive publicity product efficacy of product of pre- preventing thrombosis on the market, and product quality is very different, makees purposes
Diameter is unintelligible, seriously misguides the consumer, and brings injury to its body and psychology, and cardiovascular disease increases increasingly, seriously affects
The quality of life of crowd,
To solve the above-mentioned problems, the present invention provides a kind of functional food of thrombolysis prevention cardiovascular disease and its preparation sides
Method, the tablet of thrombolysis prevention cardiovascular disease, it is ensured that the effect of product, preparation method is easy to industrialize, adaptation range
The characteristics such as wide.
Summary of the invention
The embodiment of the invention provides a kind of thrombolysis and the functional foods and preparation method thereof of prevention cardiovascular disease, should
Thrombolysis and the functional food for preventing cardiovascular disease prove there is thrombolysis and prevention painstaking effort through in vitro test and animal function test
The healthcare function of pipe disease, can effectively thrombolysis and its prevention cardiovascular disease and safely and effectively, have no toxic side effect.
It is an advantage of the invention to provide a kind of functional food of thrombolysis prevention cardiovascular disease and its preparations
Method is guidance with Basic Theories of Chinese Medicine, in combination with modern pharmacological research, it is ensured that the effect of product；
It is still another object of the present invention to provide a kind of functional food of thrombolysis prevention cardiovascular disease and its preparation sides
The auxiliary materials such as cornstarch are added in method, and the tablet formulation for being suitable for taking is made and improves relative to vegetable drug is directly taken
The bioavilability of product；
It is still another object of the present invention to provide a kind of functional food of thrombolysis prevention cardiovascular disease and its preparation sides
Method, method is easily operated, and repeatability is high, and the tablet prepared is safe and effective, and long-term use has no toxic side effect.
In order to achieve the above objectives, the embodiment of the present invention adopts the following technical scheme that
A kind of thrombolysis and the functional food for preventing cardiovascular disease, the thrombolysis and the functional food for preventing cardiovascular disease
Effective component including following percentage:
Natto extract 5 ~ 25%, pheretima protein extract 4 ~ 15%, grape extract 0.1 ~ 10%, haw thorn extract 0.1 ~ 10%,
Rhizoma Polygonati extract 0.1 ~ 10%.
Further, the thrombolysis and prevent cardiovascular disease functional food include following percentage it is effective at
Point:
Natto extract 5 ~ 20%, pheretima protein extract 4 ~ 10%, grape extract extract 0.1 ~ 7%, haw thorn extract 0.1 ~
7%, Rhizoma Polygonati extract 0.1 ~ 7%.
Further, the vigor of the Nattokinase in the natto extract is 2000-5000FU/g.
Further, the total protein content in the pheretima protein extract is 50% ~ 90%.
Further, the procyanidin content of the grape extract is 20% ~ 95%.
Further, the general flavone content of the haw thorn extract is 1% ~ 10%.
Further, the total starches content of the Rhizoma Polygonati extract is 10% ~ 50%.
Further, the dosage form of the functional food of the thrombolysis prevention cardiovascular disease is tablet, capsule, granule
In any one peroral dosage form.
A kind of thrombolysis and prevent cardiovascular disease functional food preparation method, the method be used to prepare thrombolysis and
Prevent the functional food of cardiovascular disease, described method includes following steps:
Each Chinese medicine material extract percentage is weighed by the formula of the functional food of thrombolysis prevention cardiovascular disease；
By mixing, granulation, dry, whole grain after each Chinese medicine material extract components sieve powder, particle is made；
By the particle and auxiliary material mixture or directly by the mixture direct tablet compressing, tablet is obtained.
Further, the method for granulating be raw extract after sterilization mixture in be added its weight 10~
The ethyl alcohol that 20% concentration is 60~85% crosses the granulation of 18 meshes after soft material is made；The temperature of the drying is 50~60 DEG C, the time
For 2~4h.
Preferably, natto extract 5 ~ 25% in the step 1, pheretima protein extract 4 ~ 15%, grape extract mention
Take object 0.1 ~ 10%, haw thorn extract 0.1 ~ 10%, Rhizoma Polygonati extract 0.1 ~ 10%.
The present invention is the extract of Chinese herbal medicine in functional food allowed band, can be bought from market, and medicinal material is with specific
Method extract and prepared by the proportion.Wherein, natto extract main component is Nattokinase, Nattokinase
(nattokinase abbreviation NK) is a kind of Proteinkinase, is in soybean isoflavone by natto strain by Bacillus subtilis natto from Traditional Japanese Food
A kind of serine protease that (Bacillus subtilislnatto) is generated.With thrombus, blood viscosity is reduced, is improved
The effects of blood circulation, softening and increase blood vessel elasticity.Pharmacological action: Nattokinase is at low cost compared with other thrombolytic drugs,
Safety is good, molecular weight is small, oral result is good, thrombolysis activity is high, acting duration is long etc., is expected to be developed as a kind of market
The strong novel thrombolytic medicament of competitiveness.Direct thrombolysis: fibrin (thrombosed fibre of the Nattokinase to cross-linked state
Fibrillarin) it is particularly sensitive it can directly be degraded, on plasma fibrin without influence, be not easy to cause bleeding.Indirect thrombolysis: swash
Endothelial tube of invigorating blood circulation generates endogenous fiber zymoexcitator (T-PA).The prokinase for activating kidney to generate becomes active urine and swashs
Enzyme.Dissolve plasminogen activator inhibitor, it is ensured that thrombolytic effect.Chi Dongsheng et al. research discovery: novel thrombolytics-is received
Beans kinases.Show to pass through increasing high density lipoprotein cholesterol (HDL- research shows that natto crude extract can reduce blood lipid level
C), low density lipoprotein cholesterol (LDL-C) regulating lipid metabolism is reduced, there is lipoid peroxidization resistant, in prevention of arterial
It plays a role in atherosis forming process.Also there is study of anti-atherogenic effect, the effect of Ischemic myocardium.Yang Yaping
Et al. research discovery: the health-care efficacy of Nattokinase.Show that Nattokinase has inhibit platelet aggregation, reduce hypertension, change
The effects of kind lectin from hemolymph.
Pheretima activated protein (Earthworm active protein, EWAP) is that one kind contains fibrinolytic in pheretima medicinal material
The biological activity protein of the Multiple components such as enzyme, Lumbrokinase, nucleic acid, microelement；The short chain such as fibrinolysin, Lumbrokinase in EWAP
Small-molecule substance, after entering venule and arteriole, by the fibrinoclase member in activation thrombus, being converted into has
Active fibrinolytic enzymes fibrin promotees to activate the differentiation characteristic of vascular endothelial cell when thrombus
It is regenerated into capilary, establishes offshoot circulation, adjust blood pressure, improve hemorheology, improve atherosclerosis and hemangioma.
The main composition of grape extract is procyanidine, and procyanidine belongs to condensed tannin, is widely present in plant
A kind of polyphenolic substance at the positions such as core, skin or the seed of object.With powerful antioxidant activity, anticancer activity and protection painstaking effort
The function of pipe is widely used in cosmetics, health food, medicine trade field.Pharmacological action: 1) inoxidizability acts on；2) it protects
Shield heart blood vessel function；Resist myocardial ischemia reperfusion injury, antiatherosclerosis, effect for reducing fat；Antihypertensive effect, antiplatelet are solidifying
It is poly-, the protective effect to vascular endothelial cell；3) capillary permeability, anti-inflammatory, antioedematous are reduced；Peace times et al. research hair
Existing, grape pip procyanidin is to cardiovascular protective effect.Its free radical scavenging ability can resist myocardial ischemia reperfusion injury,
By inhibiting the oxidation antiatherosclerosis of low-density lipoprotein, and has and reduce blood pressure, adjust the painstaking effort such as blood lipid
Disease in terms of pipe.Sun Yun et al. is the study found that grape pip procyanidin antioxidation, grape pip procyanidin have very strong
Oxidation resistance, in linoleic acid and liposomal systems, the antioxidant activity of procyanidine is higher than VC and VE, and with VC, VE
With synergistic function.
Hawthorn also cries large-fruited Chinese hawthorn, red fruit, kermes fruit, is the dry mature fruit of rosaceous plant large-fruited Chinese hawthorn or hawthorn, matter
Firmly, pulp is thin, sour-sweet moderate, unique flavor.Hawthorn has very high nutritive value and medical value, and the elderly often eats haw products
It can whet the appetite, improve sleep, keep constant, the prevention of arterial atherosis of calcium in bone and blood, therefore hawthorn is considered as
" life prolonging food ".Hawthorn mainly contains flavonoids, oligomeric flavanoids, organic acid, microelement, in addition also contains triterpene
The ingredients such as class, steroid and organic amine.Pharmacological action: 1) antihypertensive effect: hawthorn has expansion peripheral blood vessel and has persistently
Antihypertensive effect, especially to the antihypertensive effect duration longest of cold-blooded animal.2) Adjust-blood lipid: hawthorn fruit total flavone is shown significantly
Lipid-regulating effect has obvious protective function to rat aorta function damage caused by hyperlipidemia, and Chen Zhiqian is cooperated with hawthorn to determine
Black soup treat dyslipidemia patient 65 show treatment after TC, LDL-C be remarkably decreased, before and after treatment relatively, difference has very
Significant meaning, it is efficient up to 89.2%.3) treating cerebral ischemia: haw thorn leaf total flavone can significantly improve model mice brain group
Knit LDH and SOD vigor, focal cerebral ischemia-reperfusion injury Mice brain tissues have a significant protective effect, mechanism and anti-
It aoxidizes related.4) act on hemorheology: 3 dosage of hawthorn fruit total flavone (80,40,20 g/kg) have reduction stasis syndrome
The function of promoting blood circulation to disperse blood clots of rat model blood contrast viscosity, Plasma Viscosity and hematocrit.The centering of hawthorn alcohol extracting thing, undercut are complete
Blood specific viscosity has significant decrease effect.
Rhizoma polygonati, also known as: polygonatum sibiricum Redoute, yellow chicken dish, pen tube dish, claw ginseng, tendrilleaf solomonseal rhizome, achickenclaw ginseng.The effect of rhizoma polygonati, is main
It is to invigorate the spleen and benefit qi, it is long to cure mainly weakness of the spleen and the stomach, fatigue and asthenia, dry deficiency of food, Heat Diabetes, deficiency syndrome of the lung cough caused by dryness, overstrain cough for nourshing kidney moistening lung
The diseases such as cough, kidney deficiency dizziness, soreness and weakness of waist and knees, poliosis.Chemical component mainly has Siberian solomonseal rhizome polysaccharide, steroid saponin and a variety of pairs of human bodies
The compounds such as beneficial amino acid and lignanoid, alkaloid and Anthraquinones.Pharmacological action 1) influence to blood glucose: rabbit stomach-filling is yellow
Smart medicinal extract, blood-sugar content increase gradually, then reduce.Huang jing extract excessively high to blood glucose caused by adrenaline is in significantly inhibit
Effect.2) antifatigue effect: 17.67% concentration 0.3ml/ of rhizoma polygonati decoction is only injected intraperitoneally, and can extend mouse swimming time.3) resist
Oxidation: 20% concentration of rhizoma polygonati decocting liquid, 13ml/ only feed drink, continuous 27 days, keep mouse liver superoxide dismutase (SOD) living
Property increase, myocardium lipofuscin content reduces；4) delaying senility function: rhizoma polygonati decoction, 20% concentration impregnate mulberry leaf and feed silkworm, has
Extend the effect of silkworm larva phase.5) anastalsis: rhizoma polygonati methanolic extract 40mg/, n-butanol fraction 20mg/, water layer
Only, intraperitoneal injection freezes dry ice-methanol mouse tail 1 minute to part 20mg/, and the experiment of back-end crop method shows there is anastalsis,
Reduce mouse amount of bleeding.6) to Cardiovascular: rhizoma polygonati aqueous extract 0.16-0.26g/kg intravenous injection, hence it is evident that increase anesthesia
Dog coronary flow；1.5g/kg intravenous injection has antagonism to rabbit myocardial ischemia caused by pituitrin, after fighting hypophysis
T wave caused by foline increases, and T wave is promoted to restore in advance extremely；12g/kg intraperitoneal injection, can enhance tolerance of the mouse to anoxic
Power.
Beneficial effects of the present invention:
(1) tablet of thrombolysis prevention cardiovascular disease provided by the invention, formula is guidance with Basic Theories of Chinese Medicine, is tied simultaneously
Close modern pharmacological research, it is ensured that the effect of product.
(2) tablet of thrombolysis prevention cardiovascular disease provided by the invention, is added soybean oil, the auxiliary materials such as beeswax are made
Suitable for the soft capsule preparation taken, the bioavilability of product is improved, and easy to carry and transport.
(3) tablet of thrombolysis prevention cardiovascular disease provided by the invention, this formula pass through external thrombolysis and internal animal
Efficacy validation, it was demonstrated that this formula has effects that significant thrombolysis prevention cardiovascular disease.
(4) thrombolysis provided by the invention prevents the tablet of cardiovascular disease, and selected each medicine is the medicine of national regulation in side
Homologous raw material is eaten, is strictly limited in a certain range in dosage, so safely and effectively, having no toxic side effect, can be eaten for a long time.
(5) tablet of thrombolysis prevention cardiovascular disease provided by the invention, can prevent cardiovascular disease, inhibit blood platelet
Glutinous collection, dissolves internal thrombus, adjusts blood lipid, and especially to middle-aged and the old blood vessel blockage person, the three high patients person has remarkable efficacy.
(6) functional food and preparation method thereof of thrombolysis prevention cardiovascular disease provided by the invention, by specific
Effective component, it is high to prepare thrombolysis prevention cardiovascular disease, the bioavilability of product, and tablet easy to carry and transport.
Detailed description of the invention
Fig. 1 is the dissolution rate that product of the present invention dissolves external thrombus；
Fig. 2 is the schematic diagram that product of the present invention dissolves external thrombus.
Specific embodiment
In order to make the object, technical scheme and advantages of the embodiment of the invention clearer, below in the embodiment of the present invention
Technical solution is clearly and completely described, it is clear that described embodiments are some of the embodiments of the present invention, rather than complete
The embodiment in portion.Based on the embodiments of the present invention, those of ordinary skill in the art are without making creative work
Every other embodiment obtained, shall fall within the protection scope of the present invention.
It should be appreciated that such as " having ", "comprising" and " comprising " term used herein are not precluded one or more
A other combined presence or addition.
Embodiment 1
A kind of functional food and preparation method thereof of thrombolysis prevention cardiovascular disease, the raw material including following percentage:
Natto extract 5%, Pheretima extract 10%, grape extract 0.1%, haw thorn extract 5%, Rhizoma Polygonati extract 3%, starch
60%, carboxyrnethyl starch sodium 13%, magnesium stearate 1%, film coating agent 2.9%.
Embodiment 2
A kind of functional food and preparation method thereof of thrombolysis prevention cardiovascular disease, the raw material including following percentage:
Natto extract 8%, Pheretima extract 4%, grape extract 0.5%, haw thorn extract 8%, Rhizoma Polygonati extract 0.5%, starch
69%, carboxyrnethyl starch sodium 8%, magnesium stearate 0.5%, film coating agent 1.5%.
Embodiment 3
A kind of functional food and preparation method thereof of thrombolysis prevention cardiovascular disease, the raw material including following percentage:
Natto extract 10%, Pheretima extract 6%, grape extract 2%, haw thorn extract 0.1%, Rhizoma Polygonati extract 10%, starch
61.9%, carboxyrnethyl starch sodium 8%, magnesium stearate 0.5%, film coating agent 1.5%.
Embodiment 4
A kind of functional food and preparation method thereof of thrombolysis prevention cardiovascular disease, the raw material including following percentage:
Natto extract 15%, Pheretima extract 12%, grape extract 5%, haw thorn extract 2%, Rhizoma Polygonati extract 8%, starch
50%, carboxyrnethyl starch sodium 6%, magnesium stearate 0.5%, film coating agent.1.5%.
Embodiment 5
A kind of functional food and preparation method thereof of thrombolysis prevention cardiovascular disease, the raw material including following percentage:
Natto extract 20%, Pheretima extract 13%, grape extract 8%, haw thorn extract 7%, Rhizoma Polygonati extract 6%, starch
40%, carboxyrnethyl starch sodium 4%, magnesium stearate 0.5%, film coating agent.
Embodiment 6
A kind of functional food and preparation method thereof of thrombolysis prevention cardiovascular disease, the raw material including following percentage:
Natto extract 25%, Pheretima extract 15%, grape extract 10%, haw thorn extract 10%, Rhizoma Polygonati extract 4%, starch
30%, carboxyrnethyl starch sodium 4%, magnesium stearate 0.5%, film coating agent.
Embodiment 7
A kind of tablet preparing the prevention cardiovascular disease of thrombolysis described in any one of embodiment 1 to 6, comprising the following steps:
Step 1) is according to percentage, and by five kinds of effective component natto extracts 5 ~ 25%, pheretima protein extract 4 ~ 15%, grape are mentioned
Object extract 0.1 ~ 10%, haw thorn extract 0.1 ~ 10% are taken, Rhizoma Polygonati extract 0.1 ~ 10% crosses 80 meshes respectively, spare；
Step 2 extracts natto extract, pheretima protein extract, grape extract, haw thorn extract, the rhizoma polygonati after sieving
Object is placed in tank-type mixer, mixes 30min, obtains the total powder of uniform raw material；
Step 3) is to add 60% ethyl alcohol as wetting agent, material and ethyl alcohol in raw extract investment trough type mixing machine
Ratio be 10:1, softwood processed, mixing time 10min；
Step 4) puts into oscillating granulator with the softwood, and 18 meshes of installation carry out wet granulation, particle drying, drying temperature
It is 60 ± 5 DEG C, drying time 4h is sieved using 14 mesh screens.
Step 5) mixes the material with magnesium stearate, is added to trough type mixing machine, mixes 30min.Tablet press machine carries out
Tabletting is to get tablet.
Embodiment 8
A method of preparing the prevention cardiovascular disease tablet of thrombolysis described in any one of embodiment 1 to 6, including following step
It is rapid:
Step 1) is according to percentage, and by five kinds of effective component natto extracts 5 ~ 25%, pheretima protein extract 4 ~ 15%, grape are mentioned
Object extract 0.1 ~ 10%, haw thorn extract 0.1 ~ 10% are taken, Rhizoma Polygonati extract 0.1 ~ 10% crosses 80 meshes respectively；
Step 2 extracts natto extract, pheretima protein extract, grape extract, haw thorn extract, the rhizoma polygonati after sieving
Object is placed in tank-type mixer, mixes 30min, obtains the total powder of uniform raw material；
Step 3) is to add 85% ethyl alcohol as wetting agent, material and ethyl alcohol in raw extract investment trough type mixing machine
Ratio be 5:1, softwood processed, mixing time 10min；；
Step 4) puts into oscillating granulator with the softwood, and 18 meshes of installation carry out wet granulation, particle drying, drying temperature
It is 50 ± 5 DEG C, drying time 2h is sieved using 14 mesh screens.
Step 5) mixes the material with magnesium stearate, is added to trough type mixing machine, mixes 30min.Tablet press machine carries out
Tabletting is to get tablet.
Embodiment 9
A method of preparing the prevention cardiovascular disease tablet of thrombolysis described in any one of embodiment 1 to 6, including following step
It is rapid:
Step 1) is according to percentage, and by five kinds of effective component natto extracts 5 ~ 25%, pheretima protein extract 4 ~ 15%, grape are mentioned
Object extract 0.1 ~ 10%, haw thorn extract 0.1 ~ 10% are taken, Rhizoma Polygonati extract 0.1 ~ 10% crosses 120 meshes respectively；
Step 2 extracts natto extract, pheretima protein extract, grape extract, haw thorn extract, the rhizoma polygonati after sieving
Object is placed in V-type blender, mixes 30min, obtains the total powder of uniform raw material；
Step 3) is to add 75% ethyl alcohol as wetting agent, material and ethyl alcohol in raw extract investment trough type mixing machine
Ratio be 20:3, softwood processed, mixing time 10min；；
Step 4) puts into oscillating granulator with the softwood, and 18 meshes of installation carry out wet granulation, particle drying, drying temperature
It is 50 ± 5 DEG C, drying time 3h is sieved using 14 mesh screens.
Step 5) mixes the material with magnesium stearate, is added to trough type mixing machine, mixes 30min.Tablet press machine carries out
Tabletting is to get tablet.
Zoopery
1, the tablet of thrombolysis prevention cardiovascular disease provided by the invention carries out acute oral toxicity test to rat
Female, male mouse each 10 are screened, experimental group and control group are randomly divided into, by intragastric administration on mice acute toxicity testing, is seen
It examines 14 days, respectively in 0 day, 7 days, 14 days record related datas, test data is shown in Table 1.
1 acute oral toxicity test result of table
1 data of table show that active animal is normal, and Normal-weight increases, and have no adverse reaction, experimental group is with the control group death rate
0%, LD50 > 5g/kg, it was demonstrated that this product be it is nontoxic, safe, meet " Biological evaluation " and require acute toxicity testing
As a result belong to nontoxic grade result.
2, invention formulation is to lipid of mice, triglycerides, the influence (± s, n=10) of high low density lipoprotein
A experimental animal: selection Wista rat, 6~8 week old, 120~200g, male rat are randomly divided into 5 groups by weight, often
Group 10.
B experimental group and given the test agent give the time: invention formulation is formulated 2.4g/d/people (36mg/kgBW), experiment
If three dosage groups and a blank control group, are low dose group (180mg/kgBW) with 5 times of human body recommended amounts, 10 times are
Middle dose group (360mg/kgBW), 30 times are high dose group (1080mg/kgBW).Tested material is prepared with water, when tested material is given
Between be 30 days.Blank control group fills distilled water.
C experimental method: test is with first 7 d are fed with normal diet, and after adapting to environment, rat is pressed in rat number, weighing
Weight is randomly divided into 5 groups, i.e. blank control group, model control group, low, middle and high dose groups, and every group 10.Blank control group is fed
Normal diet, other groups feed high lipid food, and after raising 4 weeks, this product is pressed rat body weight stomach-filling respectively by low, middle and high dose groups
Administration, blank and model control group fill the distilled water of homogeneity.Continue 30 d, empty stomach 12h cuts tail and takes blood, measures 4 water of its blood lipid
It is flat.4 horizontal datas of blood lipid are that average value is repeated several times, and are indicated with ± s, are shown in Table 2.
Table 2 rat fat, four detected values
Table 2 rat fat, four detected values
Note: * has significant difference (P ﹤ 0.05) compared with the control group, and # has more significant sex differernce (P ﹤ compared with model control group
0.05).
As can be seen from Table 2: the product of the present invention of each dosage of orally administration rat 30 days, compared with control group, model group,
Each low, middle and high dose groups rat total cholesterol, triglycerides, high-density lipoprotein have different degrees of decline, and have conspicuousness
Difference (P ﹤ 0.05), each group low-density lipoprotein has different degrees of raising compared with model group, and has significant difference (P ﹤
0.05), show: this product, which has, adjusts blood lipid, prevents the function of cardiovascular disease.
3, the influence (± s, n=3) that product of the present invention dissolves external thrombus, is shown in Table 3.
Data of the table 3 to external thrombus dissolution function test
Note: * has significant difference (P ﹤ 0.05) compared with blank control group, and # has more significant sex differernce compared with competing product control group
(P ﹤ 0.05).
After it can be seen that thrombus grumeleuse is added in product of the present invention in table 3 and attached drawing 1, attached drawing 2, acted in water-bath
30min, control group thrombus are obviously dissolved without dissolution phenomena, product group thrombus, compared with the control group, there is significant difference (P ﹤
0.05), show: this product has significant thrombolysis effect.
In conclusion invention formulation can be substantially reduced blood lipid in Mice Body, triglycerides, high-density lipoprotein is improved
Low-density lipoprotein content, at the same external thrombolytic experiment show this product can significant thrombus grumeleuse, and have conspicuousness poor
Different, the above experimental result sufficiently shows that product of the present invention has the function of that thrombolysis prevents cardiovascular disease.
The present invention overcomes above-mentioned the deficiencies in the prior art, provide a kind of functional food of thrombolysis prevention cardiovascular disease
Product and preparation method thereof.With natto, ground dragon protein, grape, hawthorn, Rhizoma Polygonati extract is major ingredient, and natto extract enzyme activity is
2000-2500IU/g, grape extract procyanidins content is up to 20% or more, and general flavone content is 5% in haw thorn extract；It is yellow
Total starches content is 20% or more in essence extract；
This product is containing albumen, flavones and polysaccharide functional food, and safety is without side-effects, while protein content is higher, and effect is aobvious
It writes, formula is guidance with Basic Theories of Chinese Medicine, in combination with modern pharmacological research, carries out compound proportion, it is ensured that the effect of product.
The auxiliary materials such as cornstarch are added, the tablet for being suitable for taking is made, compares crude drug, improves the bioavilability of product, and be convenient for
It carries and transports.In addition, proving through animal function test, have the function of that thrombolysis prevents cardiovascular disease.Meanwhile it is selected each in side
Medicine is the integration of drinking and medicinal herbs raw material that country allows, and is strictly limited in a certain range in dosage, so safely and effectively, taking nontoxic secondary work
With, it can be eaten for a long time, cardiovascular disease can be prevented, inhibit the glutinous collection of blood platelet, dissolve internal thrombus, adjust blood lipid, it is especially right
Middle-aged and the old blood vessel blockage person, the three high patients person have remarkable efficacy.
The preparation method provided through the invention, specific parameter area and under the conditions of, prepare the prevention of above-mentioned thrombolysis
The functional food of cardiovascular disease.
The above description is merely a specific embodiment, but scope of protection of the present invention is not limited thereto, any
Those familiar with the art in the technical scope disclosed by the present invention, can easily think of the change or the replacement, and should all contain
Lid is within protection scope of the present invention.Therefore, protection scope of the present invention should be based on the protection scope of the described claims.
Claims (10)
1. a kind of thrombolysis and the functional food for preventing cardiovascular disease, which is characterized in that the thrombolysis and the cardiovascular disease of prevention
The functional food of disease includes the effective component of following percentage:
Natto extract 5 ~ 25%, pheretima protein extract 4 ~ 15%, grape extract 0.1 ~ 10%, haw thorn extract 0.1 ~ 10%,
Rhizoma Polygonati extract 0.1 ~ 10%.
2. thrombolysis according to claim 1 and the functional food for preventing cardiovascular disease, which is characterized in that the thrombolysis
And the functional food of prevention cardiovascular disease includes the effective component of following percentage:
Natto extract 5 ~ 20%, pheretima protein extract 4 ~ 10%, grape extract extract 0.1 ~ 7%, haw thorn extract 0.1 ~
7%, Rhizoma Polygonati extract 0.1 ~ 7%.
3. thrombolysis according to claim 1 or 2 and the functional food for preventing cardiovascular disease, which is characterized in that described
The vigor of Nattokinase in natto extract is 2000-5000FU/g.
4. thrombolysis according to claim 1 or 2 and the functional food for preventing cardiovascular disease, which is characterized in that described
Total protein content in pheretima protein extract is 50% ~ 90%.
5. thrombolysis according to claim 1 or 2 and the functional food for preventing cardiovascular disease, which is characterized in that described
The procyanidin content of grape extract is 20% ~ 95%.
6. thrombolysis according to claim 1 or 2 and the functional food for preventing cardiovascular disease, which is characterized in that described
The general flavone content of haw thorn extract is 1% ~ 10%.
7. thrombolysis according to claim 1 or 2 and the functional food for preventing cardiovascular disease, which is characterized in that described
The total starches content of Rhizoma Polygonati extract is 10% ~ 50%.
8. thrombolysis according to claim 1 or 2 and the functional food for preventing cardiovascular disease, which is characterized in that described
Thrombolysis prevents the dosage form of the functional food of cardiovascular disease as any one peroral dosage form in tablet, capsule, granule.
9. the preparation method of a kind of thrombolysis and the functional food of prevention cardiovascular disease, which is characterized in that the method is used for
It prepares the thrombolysis as described in any one of claim 1-8 and prevents the functional food of cardiovascular disease, the method packet
Include following steps:
Each Chinese medicine material extract percentage is weighed by the formula of the functional food of thrombolysis prevention cardiovascular disease；
By mixing, granulation, dry, whole grain after each Chinese medicine material extract components sieve powder, particle is made；
By the particle and auxiliary material mixture or directly by the mixture direct tablet compressing, tablet is obtained.
10. according to the method described in claim 9, it is characterized in that, the method for granulating is raw extract after sterilization
Mixture in the ethyl alcohol that the concentration of its weight 10~20% is 60~85% is added, be made after soft material and cross the granulation of 18 meshes；It is described
Dry temperature is 50~60 DEG C, and the time is 2~4h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710881042.4A CN109549206A (en) | 2017-09-26 | 2017-09-26 | A kind of thrombolysis and the functional food and preparation method thereof for preventing cardiovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710881042.4A CN109549206A (en) | 2017-09-26 | 2017-09-26 | A kind of thrombolysis and the functional food and preparation method thereof for preventing cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109549206A true CN109549206A (en) | 2019-04-02 |
Family
ID=65862726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710881042.4A Pending CN109549206A (en) | 2017-09-26 | 2017-09-26 | A kind of thrombolysis and the functional food and preparation method thereof for preventing cardiovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109549206A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112603994A (en) * | 2020-12-24 | 2021-04-06 | 陕西中鸿科瑞再生医学研究院有限公司 | Composition for daily prevention and treatment of microthrombus and application thereof |
| CN113368223A (en) * | 2020-02-25 | 2021-09-10 | 张旺凡 | A Chinese medicinal compound dispersible tablet for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634291A (en) * | 2004-10-26 | 2005-07-06 | 辽宁省血栓病中西医结合医疗中心 | Chinese traditional medicine with thrombus eliminating and brain caring function and preparation method thereof |
| CN1799627A (en) * | 2005-01-05 | 2006-07-12 | 张振中 | Natto kinase oral liquid and its manufacturing method |
| CN101683416A (en) * | 2008-09-22 | 2010-03-31 | 上海申畅生物科技有限公司 | Natural composition for prevention and control of cardiovascular and cerebrovascular diseases, preparation method and uses thereof |
| CN102349963A (en) * | 2011-10-20 | 2012-02-15 | 新时代健康产业（集团）有限公司 | Health care product for preventing microthrombus from forming and preparation method thereof |
| CN102716471A (en) * | 2012-07-03 | 2012-10-10 | 童长虹 | Anti-hyperlipidemia health-care product |
| CN103462025A (en) * | 2013-09-29 | 2013-12-25 | 厦门中药厂有限公司 | Health food assisting in reducing blood fat and preparation method and application thereof |
| CN104510902A (en) * | 2013-10-08 | 2015-04-15 | 肖延斌 | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases |
-
2017
- 2017-09-26 CN CN201710881042.4A patent/CN109549206A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634291A (en) * | 2004-10-26 | 2005-07-06 | 辽宁省血栓病中西医结合医疗中心 | Chinese traditional medicine with thrombus eliminating and brain caring function and preparation method thereof |
| CN1799627A (en) * | 2005-01-05 | 2006-07-12 | 张振中 | Natto kinase oral liquid and its manufacturing method |
| CN101683416A (en) * | 2008-09-22 | 2010-03-31 | 上海申畅生物科技有限公司 | Natural composition for prevention and control of cardiovascular and cerebrovascular diseases, preparation method and uses thereof |
| CN102349963A (en) * | 2011-10-20 | 2012-02-15 | 新时代健康产业（集团）有限公司 | Health care product for preventing microthrombus from forming and preparation method thereof |
| CN102716471A (en) * | 2012-07-03 | 2012-10-10 | 童长虹 | Anti-hyperlipidemia health-care product |
| CN103462025A (en) * | 2013-09-29 | 2013-12-25 | 厦门中药厂有限公司 | Health food assisting in reducing blood fat and preparation method and application thereof |
| CN104510902A (en) * | 2013-10-08 | 2015-04-15 | 肖延斌 | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368223A (en) * | 2020-02-25 | 2021-09-10 | 张旺凡 | A Chinese medicinal compound dispersible tablet for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method |
| CN112603994A (en) * | 2020-12-24 | 2021-04-06 | 陕西中鸿科瑞再生医学研究院有限公司 | Composition for daily prevention and treatment of microthrombus and application thereof |
| CN112603994B (en) * | 2020-12-24 | 2024-03-12 | 陕西中鸿科瑞再生医学研究院有限公司 | Composition for daily prevention and treatment of microthrombus and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104873763A (en) | Health-care product for conditioning Qi deficiency constitution | |
| CN102872306A (en) | Compound selenium Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN106616283A (en) | Hypertension, hyperlipidemia and hyperglycemia reducing nutritional powder and preparation method thereof | |
| CN104739925A (en) | Composition for treating acnes and preparation method for composition | |
| CN111919934A (en) | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof | |
| CN105707876B (en) | It is a kind of that there is the dietary composition and its preparation method and application stablized and dissolve patch | |
| CN109549206A (en) | A kind of thrombolysis and the functional food and preparation method thereof for preventing cardiovascular disease | |
| CN112791175A (en) | Chinese and western medicine composition for improving human body metabolism function and discharging metabolic waste and preparation method thereof | |
| CN100551460C (en) | One hilum is treated device | |
| CN108813465A (en) | A kind of fig function chewable tablets and preparation method thereof | |
| CN107494817A (en) | A kind of hypoglycemic tea | |
| CN104645077A (en) | Traditional Chinese medicine preparation for preventing and treating ischemic cerebrovascular disease and preparation method of traditional Chinese medicine preparation | |
| KR20200025245A (en) | Preparation for improving blood circulation comprising mixed oriental medicinal extracts | |
| CN107927279A (en) | A kind of health protection tea for treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN104258300A (en) | Traditional Chinese medicine preparation for treating apoplexy sequela due to vital energy deficiency and blood stasis and preparation method of traditional Chinese medicine preparation | |
| CN106822684A (en) | Prevent and treat Chinese medicine composition, medicine of hyperuricemia and its preparation method and application | |
| KR101934810B1 (en) | Preparation for improving blood circulation comprising oriental medicinal extracts | |
| CN106490604A (en) | A kind of anti-oxidant Green Tea Extract health care product and preparation method thereof | |
| CN106260348A (en) | A kind of SANYE Jingya Daipao Teas and preparation method thereof | |
| CN112294925A (en) | A medicine for treating gout, gastropathy and constipation, and its preparation method | |
| KR101093006B1 (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same | |
| CN105055856B (en) | A kind of Tea Pigment Chinese medicine composition and its preparation method and application for treating cardiovascular and cerebrovascular disease | |
| CN109289017A (en) | For clearing up the composition and preparation method of blood vessel and blood | |
| CN112076305A (en) | A Chinese medicinal oral and topical stock solution mixture for treating metabolic syndrome and resisting bacteria and inflammation | |
| CN106728631A (en) | A kind of Chinese medicine preparation for treating hyperpietic with atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 710042 room 112, floor 1, building A2, standard workshop community, Xi'an Textile Industrial Park, Baqiao District, Xi'an City, Shaanxi Province Applicant after: Shaanxi bairuiheng Health Technology Co.,Ltd. Address before: 523808 room 10, floor 1, building 1, Guantai biotechnology cooperation center, No. 1 Taoyuan Road, Taiwan High Tech Park, Songshanhu high tech Industrial Park, Dongguan City, Guangdong Province Applicant before: DONGGUAN NATURAL SALUTEM HEALTH TECHNOLOGY CO.,LTD. |
|
| CB02 | Change of applicant information | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190402 |
|
| WD01 | Invention patent application deemed withdrawn after publication |